Other Cancer: Clinical Trials

3 trials for Other Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Active not recruiting 1, Recruiting 1, Unknown 1
Phase 11Recruiting 1

Follow Other Cancer: new trials by email Literature Review of Other Cancer trials Research Report on Other Cancer

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm
Phase 1 / Phase 2RecruitingPMV Pharmaceuticals, Inc3002020-10-292026-10-02
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer
Phase 2UnknownFondazione per la Medicina Personalizzata4002020-10-072023-10-03
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
ruxolitinib - Other Cancer
Phase 2Active not recruitingMassachusetts General Hospital502019-04-192025-11-10

Narrower conditions

Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Colorectal Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Gallbladder Neoplasms (1)  ·  Gastrointestinal Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Ovarian Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)  ·  Triple Negative Breast Neoplasms (1)

Broader conditions

Breast Diseases (2)  ·  Bronchial Neoplasms (2)  ·  Carcinoma, Bronchogenic (2)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Gastrointestinal Diseases (2)  ·  Lung Diseases (2)  ·  Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Respiratory Tract Diseases (2)  ·  Respiratory Tract Neoplasms (2)  ·  Skin Diseases (2)  ·  Skin and Connective Tissue Diseases (2)  ·  Thoracic Neoplasms (2)  ·  Adnexal Diseases (1)

Interventions

Ado-Trastuzumab Emtansine (1)  ·  Alpelisib (1)  ·  Erlotinib Hydrochloride (1)  ·  Everolimus (1)  ·  Ipilimumab (1)  ·  Lapatinib (1)  ·  Nivolumab (1)  ·  Trastuzumab (1)  ·  Vemurafenib (1)  ·  alectinib (1)  ·  atezolizumab (1)  ·  brigatinib (1)  ·  cobimetinib (1)  ·  entrectinib (1)  ·  ipatasertib (1)

Sponsors

Fondazione per la Medicina Personalizzata (1)  ·  Massachusetts General Hospital (1)  ·  PMV Pharmaceuticals, Inc (1)

Countries

Italy (2)  ·  United States (2)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Andrea Botticelli (1)  ·  Marc Fellous, MD (1)  ·  Paolo Marchetti (1)  ·  Zachariah DeFilipp, MD (1)

Results publications

PMID 38485149, PMID 39365992, PMID 40543428, PMID 40932470, PMID 41023484, PMID 41740031, PMID 41963505

NIH funding

2018 (1)